Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.

S Gruhn, J Witte, W Greiner, O Damm, M Dietzsch, R Kramer, M Knuf

Journal: Vaccine 2022;40(13):1932-1947

PMID: 35227520

Abstract

INTRODUCTION

Invasive meningococcal disease (IMD) is a notifiable disease in Germany and other European countries. Due to the high lethality of the disease and the risk of long-term consequences, IMD prevention is of high public health relevance despite the low number of cases in the population. This study aims to describe key epidemiological and economic parameters of IMD in Germany to support national decision-making processes for implementing enhanced prevention measures.

METHODS

Based on a systematic literature review in PubMed and EMBASE, all publications on the burden of disease and costs of IMD published up to May 2020 were evaluated. Additionally, notification data were used to report the annual case numbers and incidence of IMD in Germany until the end of 2019.

RESULTS

Thirty-six studies were included, of which 35 reported data on the epidemiological burden of disease and three reported data on economic aspects of IMD. The type of reported endpoints and results on the incidence of IMD differed widely by reporting year, population, and data source used. Most of the data are reported without specific information about a serogroup. Data on the economic burden of disease and healthcare resource use are scarce. Based on mandatory notification data, a decrease in the incidence of notified IMD cases has been observed since 2004. Currently, the nationwide annual incidence in Germany is at 0.3 cases per 100,000 persons and has gradually decreased. While the overall decline is mainly attributable to MenB, cases with MenY and MenW are the only ones that have increased on a low level in recent years.

CONCLUSION

While IMD is a rare disease, high direct and indirect costs illustrate the relevance of the disease for patients, caregivers, as well as for the health care system. Future research should concentrate on quantifying the long-term economic burden and indirect costs of meningococcal disease. Integrated IMD surveillance with isolate characterisation remains crucial to inform public health policies.

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Address: Department for Health Economics and Health Care Management, School of Public Health, Bielefeld University, Germany. Electronic address: [email protected].; Department for Health Economics and Health Care Management, School of Public Health, Bielefeld University, Germany; Vandage GmbH, Bielefeld, Germany. Electronic address: [email protected].; Department for Health Economics and Health Care Management, School of Public Health, Bielefeld University, Germany. Electronic address: [email protected].; Sanofi-Aventis Deutschland GmbH, Germany. Electronic address: [email protected].; Sanofi-Aventis Deutschland GmbH, Germany. Electronic address: [email protected].; Sanofi-Aventis Deutschland GmbH, Germany. Electronic address: [email protected].; Klinik für Kinder- und Jugendmedizin, Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany; Klinik für Kinder- und Jugendmedizin, Klinikum Worms gGmbH, Worms, Germany; Pädiatrische Infektiologie, Universitätsmedizin Mainz, Germany. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.